141 related articles for article (PubMed ID: 37364231)
21. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
22. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
23. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
24. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
25. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
26. Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.
Allen CE; Laetsch TW; Mody R; Irwin MS; Lim MS; Adamson PC; Seibel NL; Parsons DW; Cho YJ; Janeway K;
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28376230
[TBL] [Abstract][Full Text] [Related]
27.
Nikanjam M; Tinajero J; Barkauskas DA; Kurzrock R
Mol Cancer Ther; 2021 Jun; 20(6):1072-1079. PubMed ID: 33722853
[TBL] [Abstract][Full Text] [Related]
28. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
[TBL] [Abstract][Full Text] [Related]
29. Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.
Puzanov I; Ribas A; Robert C; Schachter J; Nyakas M; Daud A; Arance A; Carlino MS; O'Day SJ; Long GV; Margolin KA; Dummer R; Schadendorf D; Lutzky J; Ascierto PA; Tarhini A; Lin J; Mogg R; Homet Moreno B; Ibrahim N; Hamid O
JAMA Oncol; 2020 Aug; 6(8):1256-1264. PubMed ID: 32672795
[TBL] [Abstract][Full Text] [Related]
30. Epidermal Growth Factor Receptor Inhibitors and Other Tyrosine Kinase Inhibitors for Solid Tumors.
Ruiz-Camps I; Aguilar-Company J
Infect Dis Clin North Am; 2020 Jun; 34(2):257-270. PubMed ID: 32334988
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
[TBL] [Abstract][Full Text] [Related]
32. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
33. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
[TBL] [Abstract][Full Text] [Related]
34. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
35. Histiocytic neoplasms in the era of personalized genomic medicine.
Durham BH; Diamond EL; Abdel-Wahab O
Curr Opin Hematol; 2016 Jul; 23(4):416-25. PubMed ID: 27101528
[TBL] [Abstract][Full Text] [Related]
36. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
Malaguarnera R; Chen KY; Kim TY; Dominguez JM; Voza F; Ouyang B; Vundavalli SK; Knauf JA; Fagin JA
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1976-87. PubMed ID: 25029414
[TBL] [Abstract][Full Text] [Related]
37. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
38. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Dabrafenib in Pediatric Patients with
Hargrave DR; Bouffet E; Tabori U; Broniscer A; Cohen KJ; Hansford JR; Geoerger B; Hingorani P; Dunkel IJ; Russo MW; Tseng L; Dasgupta K; Gasal E; Whitlock JA; Kieran MW
Clin Cancer Res; 2019 Dec; 25(24):7303-7311. PubMed ID: 31811016
[TBL] [Abstract][Full Text] [Related]
40. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma.
Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA
Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
